Adverse events associated with bimekizumab for moderate-to-severe plaque psoriasis: A retrospective, multicenter, post-hoc analysis.
作者信息
Zangenah Nikki, Vazquez-Machado Maria, Loranger Nicole, Elshaboury Soha, Hashemi Kimberly, LaChance Avery H
机构信息
Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts.
University of Massachusetts T. H. Chan Medical School, Worcester, Massachusetts.
出版信息
JAAD Int. 2025 Mar 18;20:54-55. doi: 10.1016/j.jdin.2025.02.001. eCollection 2025 Jun.
Abstract
摘要
相似文献
1
Adverse events associated with bimekizumab for moderate-to-severe plaque psoriasis: A retrospective, multicenter, post-hoc analysis.与比美吉珠单抗治疗中度至重度斑块状银屑病相关的不良事件：一项回顾性、多中心、事后分析。
JAAD Int. 2025 Mar 18;20:54-55. doi: 10.1016/j.jdin.2025.02.001. eCollection 2025 Jun.
2
Efficacy and Safety of bimekizumab in elderly patients: real-world multicenter retrospective study - IL PSO (Italian Landscape Psoriasis).比美吉珠单抗治疗老年患者的疗效和安全性：真实世界多中心回顾性研究-IL PSO（意大利银屑病景观）。
J Dermatolog Treat. 2024 Dec;35(1):2393376. doi: 10.1080/09546634.2024.2393376. Epub 2024 Aug 20.
3
Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study-IL PSO (Italian landscape psoriasis).比美吉珠单抗治疗斑块状银屑病的有效性和安全性：一项真实世界多中心研究-IL PSO（意大利银屑病情况）
Front Med (Lausanne). 2023 Aug 8;10:1243843. doi: 10.3389/fmed.2023.1243843. eCollection 2023.
4
Bimekizumab-bkzx for the Treatment of Plaque Psoriasis: A Drug Review.用于治疗斑块状银屑病的比美吉珠单抗-bkzx：药物综述
Ann Pharmacother. 2025 Jun;59(6):577-584. doi: 10.1177/10600280241288553. Epub 2024 Oct 19.
5
Long-Term Efficacy and Safety of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: Updated Systematic Literature Review and Network Meta-analysis.比美吉珠单抗及其他生物制剂治疗中度至重度斑块状银屑病的长期疗效和安全性：更新的系统文献综述和网状Meta分析
Dermatol Ther (Heidelb). 2024 Nov;14(11):3133-3147. doi: 10.1007/s13555-024-01302-0. Epub 2024 Nov 1.
6
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.比美吉珠单抗与乌司奴单抗治疗中度至重度斑块型银屑病（BE VIVID）：一项为期 52 周、多中心、双盲、活性对照和安慰剂对照的 3 期临床试验的疗效和安全性。
Lancet. 2021 Feb 6;397(10273):487-498. doi: 10.1016/S0140-6736(21)00125-2.
7
Efficacy of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: A Systematic Literature Review and a Network Meta-Analysis.比美吉珠单抗及其他生物制剂治疗中度至重度斑块状银屑病的疗效：系统文献综述与网状Meta分析
Dermatol Ther (Heidelb). 2022 Aug;12(8):1777-1792. doi: 10.1007/s13555-022-00760-8. Epub 2022 Jul 7.
8
Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.比美吉珠单抗治疗中重度斑块型银屑病的疗效和安全性（BE READY）：一项多中心、双盲、安慰剂对照、随机撤药阶段 3 期临床试验。
Lancet. 2021 Feb 6;397(10273):475-486. doi: 10.1016/S0140-6736(21)00126-4.
9
Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: a meta-analysis of randomized clinical trials.比美吉珠单抗治疗中度至重度斑块状银屑病：一项随机临床试验的荟萃分析
Ther Adv Chronic Dis. 2023 Apr 4;14:20406223231163110. doi: 10.1177/20406223231163110. eCollection 2023.
10
Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluation.中度至重度斑块状银屑病患者的比美吉珠单抗治疗：药物安全性评估
Expert Opin Drug Saf. 2023 Jan-Jun;22(5):355-362. doi: 10.1080/14740338.2023.2218086. Epub 2023 Jun 19.
本文引用的文献
1
Bimekizumab as treatment for moderate to severe chronic plaque psoriasis: Real world clinical experience from a district general hospital setting.比美吉珠单抗治疗中度至重度慢性斑块状银屑病：来自一家区综合医院的真实世界临床经验。
Skin Health Dis. 2024 Jun 27;4(5):e418. doi: 10.1002/ski2.418. eCollection 2024 Oct.
2
Real-world experience of bimekizumab for adult patients with plaque psoriasis: A 52-week multicenter retrospective study.成人斑块状银屑病患者使用比美吉珠单抗的真实世界经验：一项为期52周的多中心回顾性研究。
J Am Acad Dermatol. 2024 Nov;91(5):936-939. doi: 10.1016/j.jaad.2024.05.085. Epub 2024 Jun 15.
3
Bimekizumab versus Secukinumab in Plaque Psoriasis.比美吉珠单抗与司库奇尤单抗治疗斑块状银屑病的疗效比较。
N Engl J Med. 2021 Jul 8;385(2):142-152. doi: 10.1056/NEJMoa2102383. Epub 2021 Apr 23.
4
Bimekizumab versus Adalimumab in Plaque Psoriasis.比美吉单抗与阿达木单抗治疗斑块状银屑病的疗效比较。
N Engl J Med. 2021 Jul 8;385(2):130-141. doi: 10.1056/NEJMoa2102388. Epub 2021 Apr 23.
5
Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study.比美克珠单抗治疗中重度斑块型银屑病患者：来自 BE ABLE 2 的 60 周结果，一项随机、双盲、安慰剂对照的 2b 期扩展研究。
J Am Acad Dermatol. 2020 Nov;83(5):1367-1374. doi: 10.1016/j.jaad.2020.05.105. Epub 2020 May 29.
Zotero 插件